Searching for Anticancer Agents and Antimalarial Agents from Madagascar

Total Page:16

File Type:pdf, Size:1020Kb

Searching for Anticancer Agents and Antimalarial Agents from Madagascar SEARCHING FOR ANTICANCER AGENTS AND ANTIMALARIAL AGENTS FROM MADAGASCAR Ende Pan A thesis submitted to the faculty of the Virginia Polytechnic Institute and State University in partial fulfillment of the requirements for the degree of Doctor of Philosophy In Chemistry Dr. David G. I. Kingston Dr. Paul R. Carlier Dr. Harry W. Gibson Dr. Brian E. Hanson Dr. James M. Tanko (December 8, 2010) Blacksburg, VA Keywords: Natural Products, Anticancer, Antimalarial, Antiproliferative, Flavonoid, Cardenolide, Diphenylpropane, Alkaloid, Sesquiterpene lactone SEARCHING FOR ANTICANCER AGENTS AND ANTIMALARIAL AGENTS FROM MADAGASCAR Ende Pan ABSTRACT In our continuing search for biologically active natural products from Madagascar as part of an International Cooperative Biodiversity Group (ICBG) program, a total of four antiproliferative extracts were studied, leading to the isolation of twelve novel compounds with antiproliferative activity against the A2780 human ovarian cancer line, and one extract with antimalarial activities was studied, which led to the isolation of five new natural products with antimalarial activities against the Dd2 and HB3 malarial parasites. The plants and their metabolites are discussed in the following order: one new xanthone and two known guttiferones from Symphonia tanalensis Jum. & H. Perrier (Clusiaceae); four new diphenyl propanes and one new cyclohepta-dibenzofuran skeleton from Bussea sakalava (Fabaceae); four new cardiac glycosides from Leptadenia madagascariensis Decne. (Apocynaceae); two new and four known alkaloids from Ambavia gerrardii (Baill.) Le Thomas (Annonaceae); five new sesquiterpene lactones from Polycline proteiformis Humbert (Asteraceae). The structures of all compounds were determined by analysis of their mass spectrometric, 1D and 2D NMR, UV and IR spectroscopic and optical rotation data. Other than structure elucidation, this dissertation also involve bioactivity evaluation of all the isolates, synthesis of two interesting alkaloids, as well as a proposal for the possible biosynthetic pathway of the new cyclohepta-dibenzofuran skeleton. ACKNOWLEDGEMENTS Firstly, I would like to thank my advisor, Dr. David G. I. Kingston, for giving me the opportunity to work in his lab at Virginia Tech. I feel grateful for his guidance, patience, concern and kindness throughout my time in Blacksburg. And I would also like to thank the other members of my committee, Drs. Paul R. Carlier, Harry W. Gibson, Brian E. Hanson, James M. Tanko, and the former member, Dr. Larry T. Taylor. Their wisdom, advice and encouragement has been greatly appreciated. Special thanks are given to Drs. Shugeng Cao and Liva Harinantenaina for teaching me so much about natural product chemistry and for providing me invaluable suggestions on research problems. I would like to thank Drs. Paul Roepe and John Alumna at Georgetown University for our collaborative effort on the antimalarial project. Without the help and support from current and some of the former members of Dr. Kingston’s group, the current work would not have been possible. So I would like to thank Ms. Peggy Brodie, Drs. Qiao Hong Chen, Yanpeng Hou, Brian Murphy, Vincent E. Rasamison, Patricia Onocha, Chao Yang, and Jun Qi, Mr. Jielu Zhao, Ms. Yixi Liu, Mr. Alex Xu, Mr. Yumin Dai and Mrs. Melody Windsor. I would also like to thank the current and former departmental analytical service staff Dr. Hugo Azurmendi, Dr. Mehdi Ashraf-Khorassani, Mr. William Bebout, Mr. Tom Glass, Mr. Geno Iannaccone, and Dr. Carla Slebodnick for their assistance. Finally, I could not come so far without love, support and encouragement from my family. I would like to thank my parents, Zexin Pan and Yun Sun for always loving me and supporting me so much over the years. I would like to thank my wife, Xian Wang, who has given up so much and always been there for me all these years. iii TABLE OF CONTENT Page LIST OF FIGURES ix LIST OF SCHEMES xi LIST OF TABLES xii I. Introduction: natural product drug discovery 1 1.1 Introduction 1 1.2 Natural product drug discovery 2 1.3 Natural products medicines from different sources 4 1.4 Anticancer agents and antimalarial agents from natural resources 7 1.5 The ICBG (International Cooperative Biodiversity Groups) program 10 References 12 II. An antiproliferative xanthone and two guttiferones of Symphonia tanalensis from the Madagascar rainforest 16 2.1 Introduction 16 2.1.1 Previous investigations of Symphonia 17 2.2.Results and Discussion 18 2.2.1 Structure elucidation of Compound 2.1 18 2.2.2 Identification of the know guttiferone I and A 21 2.2.3 Antiproliferative activities of isolated compounds 22 2.3 Experimental Section 23 iv References 29 III. Four diphenylpropanes and a cycloheptadibenzofuran from Bussea sakalava from the Madagascar dry forest 33 3.1 Introduction 33 3.1.1 Previous investigations of Bussea 34 3.2 Results and Discussion 34 3.2.1 Structure elucidation of bussealin A (3.1) 34 3.2.2 Structure elucidation of bussealin B (3.2) 36 3.2.3 Structure elucidation of bussealin C (3.3) 37 3.2.4 Structure elucidation of bussealin D (3.4) 38 3.2.5 Structure elucidation of bussealin E (3.5) 39 3.2.6 Possible biosynthesis of bussealin E (3.5) 42 3.2.7 Antiproliferative activities of bussealin A-E (3.1-3.5) 43 3.3 Experimental Section 44 References 48 IV. Cardenolides of Leptadenia madagascariensis from the Madagascar dry forest 52 4.1 Introduction 52 4.1.1 Previous investigations of Leptadenia 53 4.2 Results and Discussion 54 4.2.1 Structure elucidation of madagascarensilide A (4.1) 54 4.2.2 Structure elucidation of madagascarensilide B (4.2) 58 v 4.2.3 Structure elucidation of madagascarensilide C (4.3) 59 4.2.4 Structure elucidation of madagascarensilide D (4.4) 63 4.2.5 Antiproliferative activities of madagascarensilide A-D (4.1-4.4) 64 4.3 Experimental Section 65 References 69 V. Isolation and synthesis of antiproliferative eupolauridine alkaloids of Ambavia gerrardii from the Madagascar dry forest 73 5.1 Introduction 73 5.1.1 Previous investigations of Annonaceae 74 5.2 Results and Discussion 75 5.2.1 Structure elucidation of compound 5.1 76 5.2.2 Structure elucidation of compound 5.2 77 5.2.3 Synthesis of compounds 5.1 and 5.2 77 5.2.4 Antiproliferative activities of compounds 5.1-5.6, 5.10 and 5.11 81 5.3 Experimental Section 82 References 90 VI. Five new antimalarial pseudoguaianolides of Polycline proteiformis from the Madagascar dry forest 95 6.1 Introduction 95 6.1.1 Previous investigations of Asteraceae 95 6.2 Results and Discussion 96 vi 6.2.1 Structure elucidation of polyclinolide A (6.1) 97 6.2.2 Structure elucidation of polyclinolide B (6.2) 100 6.2.3 Structure elucidation of polyclinolide C (6.3) 101 6.2.4 Structure elucidation of polyclinolide D (6.4) 104 6.2.5 Structure elucidation of polyclinolide E (6.5) 105 6.2.6 Structure elucidation of compound 6.6 106 6.2.7 Bioactivities of polyclinolide A-E (6.1-6.5) and centaureidin (6.6) 106 6.3 Experimental Section 109 References 114 VII. Miscellaneous Plants Studied 118 7.1 Introduction 118 7.2 Anticancer extracts 118 7.2.1 Chadsia racemosa (Fabaceae) 118 7.2.2 Gastonia duplicate (Araliaceae) 119 7.2.3 Entada louvelii (Fabaceae) 119 7.2.4 Entada sp. (Fabaceae) 120 7.2.5 Leea guineensis (Vitaceae) 120 7.2.6 Droceloncia reticulate (Euphorbiaceae) 120 7.3 Antimalarial extracts 121 7.3.1 Phyllanthus muellerianus (Euphorbiaceae) 121 7.3.2 Microdemis Caseariaefoli (Pandaceae) 122 7.3.3 Majidea sp. (Sapindaceae) 123 vii 7.3.4 Terminalia septentrionalis (Combretaceae) 124 7.4 Structure elucidation on compounds isolated in Madagascar 124 References 125 VIII. General Conclusions 127 8.1 Anticancer extracts 127 8.2 Antimalarial extracts 128 APPENDIX 129 viii LIST OF FIGURES Figure 1.1 Chemical structures of 1.1-1.5 2 Figure 1.2 Chemical structures of 1.6-1.8 2 Figure 1.3 All new chemical entities, 01/1981-06/2006, by source (N ) 1184 3 Figure 1.4 Chemical structures of 1.9-1.12 4 Figure 1.5 Chemical structures of 1.13-1.15 5 Figure 1.6 Chemical structures of 1.16-1.18 6 Figure 1.7 Chemical structures of 1.19 and 1.20 6 Figure 1.8 Chemical structures of 1.21 and 1.22 7 Figure 1.9 Chemical structures of 1.23 and 1.24 8 Figure 1.10 Chemical structures of 1.25 and 1.26 8 Figure 1.11 Chemical structures of 1.27 and 1.28 9 Figure 1.12 Chemical structures of 1.29-1.31 10 Figure 2.1 Compounds isolated from Symphonia globulifera 17 Figure 2.2 Chemical structure of compound 2.1 20 Figure 2.3 NMR correlations of compound 2.1 21 Figure 2.4 Chemical structures of compound 2.2 and2.3 22 Figure 2.5 Chemical structures of compounds 2.4-2.6 22 Figure 3.1 Compounds isolated from Bussea sp. 34 Figure 3.2 Chemical structures of bussealin A-D (3.1-3.4) 36 Figure 3.3 Chemical structures of bussealin E (3.5) and 3.6 40 Figure 3.4 COSY, HMBC and NOESY correlations of 3.5 40 ix Figure 4.1 Compounds from the genus Leptadenia 53 Figure 4.2 Chemical structures of madagascarensilides A (4.1) and B (4.2) 55 Figure 4.3 a) Key COSY (bold) and HMBC (arrows) correlations for 4.1 b) Key ROESY correlations for 4.1 57 Figure 4.4 Chemical structures of madagascarensilides C (4.3) and D (4.4) 63 Figure 4.5 a) Key COSY (bold) and HMBC (arrows) correlations for 4.3 b) Key ROESY correlations for 4.3 64 Figure 5.1.
Recommended publications
  • Neena Valecha1, Deepali Savargaonkar1, Bina Srivastava1, B
    Valecha et al. Malar J (2016) 15:42 DOI 10.1186/s12936-016-1084-1 Malaria Journal RESEARCH Open Access Comparison of the safety and efficacy of fixed‑dose combination of arterolane maleate and piperaquine phosphate with chloroquine in acute, uncomplicated Plasmodium vivax malaria: a phase III, multicentric, open‑label study Neena Valecha1, Deepali Savargaonkar1, Bina Srivastava1, B. H. Krishnamoorthy Rao2, Santanu K. Tripathi3, Nithya Gogtay4, Sanjay Kumar Kochar5, Nalli Babu Vijaya Kumar6, Girish Chandra Rajadhyaksha7, Jitendra D. Lakhani8, Bhagirath B. Solanki9, Rajinder K. Jalali10, Sudershan Arora10, Arjun Roy10, Nilanjan Saha10, Sunil S. Iyer10, Pradeep Sharma10 and Anupkumar R. Anvikar1* Abstract Background: Chloroquine has been the treatment of choice for acute vivax malaria for more than 60 years. Malaria caused by Plasmodium vivax has recently shown resistance to chloroquine in some places. This study compared the efficacy and safety of fixed dose combination (FDC) of arterolane maleate and piperaquine phosphate (PQP) with chloroquine in the treatment of uncomplicated vivax malaria. Methods: Patients aged 13–65 years with confirmed mono-infection of P. vivax along with fever or fever in the previ- ous 48 h were included. The 317 eligible patients were randomly assigned to receive FDC of arterolane maleate and PQP (n 159) or chloroquine (n 158) for 3 days. Primaquine was given as an anti-relapse measure on day 3 and continued= for 14 consecutive days.= Primary efficacy analysis included assessment of the proportion of aparasitaemic and afebrile patients at 72 h. Safety endpoints were analysis of adverse events, vital signs, laboratory data, and abnor- malities on electrocardiograph. Patients participated in the study for at least 42 days.
    [Show full text]
  • Review Article Efforts Made to Eliminate Drug-Resistant Malaria and Its Challenges
    Hindawi BioMed Research International Volume 2021, Article ID 5539544, 12 pages https://doi.org/10.1155/2021/5539544 Review Article Efforts Made to Eliminate Drug-Resistant Malaria and Its Challenges Wote Amelo 1,2,3 and Eyasu Makonnen 1,2 1Department of Pharmacology and Clinical Pharmacy, School of Pharmacy, Addis Ababa University, Addis Ababa, Ethiopia 2Center for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa), Addis Ababa University, Addis Ababa, Ethiopia 3Department of Pharmacology and Toxicology, School of Pharmacy, Jimma University, Jimma, Ethiopia Correspondence should be addressed to Wote Amelo; [email protected] Received 21 January 2021; Accepted 9 August 2021; Published 30 August 2021 Academic Editor: Jane Hanrahan Copyright © 2021 Wote Amelo and Eyasu Makonnen. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Since 2000, a good deal of progress has been made in malaria control. However, there is still an unacceptably high burden of the disease and numerous challenges limiting advancement towards its elimination and ultimate eradication. Among the challenges is the antimalarial drug resistance, which has been documented for almost all antimalarial drugs in current use. As a result, the malaria research community is working on the modification of existing treatments as well as the discovery and development of new drugs to counter the resistance challenges. To this effect, many products are in the pipeline and expected to be marketed soon. In addition to drug and vaccine development, mass drug administration (MDA) is under scientific scrutiny as an important strategy for effective utilization of the developed products.
    [Show full text]
  • Update Tot 30-04-2020 1. Chloroquine and Hydroxychloroquine for The
    Update tot 30-04-2020 1. Chloroquine and Hydroxychloroquine for the Prevention or Treatment of Novel Coronavirus Disease (COVID-19) in Africa: Caution for Inappropriate Off-Label Use in Healthcare Settings. Abena PM, Decloedt EH, Bottieau E, Suleman F, Adejumo P, Sam-Agudu NA, et al. Am j trop med hyg. 2020. 2. Evaluation of Hydroxychloroquine Retinopathy Using Ultra-Widefield Fundus Autofluorescence: Peripheral Findings in the Retinopathy. Ahn SJ, Joung J, Lee BR. American journal of ophthalmology. 2020;209:35-44. http://dx.doi.org/10.1016/j.ajo.2019.09.008. Epub 2019 Sep 14. 3. COVID-19 research has overall low methodological quality thus far: case in point for chloroquine/hydroxychloroquine. Alexander PE, Debono VB, Mammen MJ, Iorio A, Aryal K, Deng D, et al. J clin epidemiol. 2020. 4. Chloroquine and Hydroxychloroquine in the Era of SARS - CoV2: Caution on Their Cardiac Toxicity. Bauman JL, Tisdale JE. Pharmacotherapy. 2020. 5. Repositioned chloroquine and hydroxychloroquine as antiviral prophylaxis for COVID-19: A protocol for rapid systematic review of randomized controlled trials. Chang R, Sun W-Z. medRxiv. 2020:2020.04.18.20071167. 6. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Colson P, Rolain J-M, Lagier J-C, Brouqui P, Raoult D. Int J Antimicrob Agents. 2020:105932-. 7. Dose selection of chloroquine phosphate for treatment of COVID-19 based on a physiologically based pharmacokinetic model. Cui C, Zhang M, Yao X, Tu S, Hou Z, Jie En VS, et al. Acta Pharmaceutica Sinica B. 2020. 8. Hydroxychloroquine; Why It Might Be Successful and Why It Might Not Be Successful in the Treatment of Covid-19 Pneumonia? Could It Be A Prophylactic Drug? Deniz O.
    [Show full text]
  • Fixed Dose Combinations Approved by Dcg (I) Since 1961 Till February, 2013
    FIXED DOSE COMBINATIONS APPROVED BY DCG (I) SINCE 1961 TILL FEBRUARY, 2013 # Name of Drug Indication Date of approval 1. Cyanocobalamine + Zinc tannic acid complex Jan-61 2. Cobalt glutamate + Copper Glycinate Aug-61 3. Fibrinolysin + Desoxyribonuclease Feb-62 4. Tablets of Norethisterone acetate + Ethinyl Nov-62 oestradiol 5. Tablets of Norethynodrel and Ethinyl Estradiol 3-methyl ether Dec-62 6. Broxyquinoline + Brobenzoxalidine May-63 7. Testosterone decanoate + Isocaproate Jan-64 8. Combination of L Oxethazaine + Aluminium hydroxide + Magnesium Hydroxide Jun-66 9. Amylobarbitone + Trifluperazine Dihydrochloride Capsule Feb-67 10. Lynestronol 2.5mg + Mestranol 0.075mg Tablet Apr-67 11. Northynodrel 2.5mg + Mestranol 0.1mg Jun-67 12. Norethisterone 2mg and Mestranol 0.1mg May-67 13. Mestranol 4mg + Ethinyloestradial 0.05mg May-67 Tablet 14. Norethisterane acetate + ethinyl estradiol May-67 15. Aluminium sodium silicate + Magnesium hydroxide + Methypolysiloxane Tablet Jun-67 16. Ammoidin + Amidine Jul-67 17. Fluocortolene + Flucortolene Caproate Jul-68 18. Norgestrel + Ethinyloestradiol Tablet Aug-68 19. Folic Acid 0.5mg + Ferrous Sulphate 150mg Jan-69 Capsule 20. Tetracycline HCl 250mg + Broxyquinoline 200mg + Brobenzoxadine 40mg Jan-69 21. Methyldopa 250mg + HCTZ 15mg Tablet Feb-69 22. dl Norgestrel + 17 alpha hydroxy progesterone caproate + Norethisterone acetate + 17 alpha Jan-69 acetoxy progesterone 23. Diphenoxylate HCl 2.5mg + Atropine Sulphate 0.025mg tablet Jul-69 24. Vitamin A,D & E Jul-69 25. Lutin 0.1gm + Vit 0.1gm + Vit K1 2.5mg + Dicalcium Phosphate 0.1gm + Carlozochrome Jul-69 Salicylate 1mg tablet 26. Vit K 1 5mg + Calcium Lactolionate 100 m g+ Carlozocrome Salicylate 2.5mg + Phenol 0.5% Jul-69 + Lignocaine Hcl 1% injection 27.
    [Show full text]
  • PHARMACOLOGY of NEWER ANTIMALARIAL DRUGS: REVIEW ARTICLE Bhuvaneshwari1, Souri S
    REVIEW ARTICLE PHARMACOLOGY OF NEWER ANTIMALARIAL DRUGS: REVIEW ARTICLE Bhuvaneshwari1, Souri S. Kondaveti2 HOW TO CITE THIS ARTICLE: Bhuvaneshwari, Souri S. Kondaveti. ‖Pharmacology of Newer Antimalarial Drugs: Review Article‖. Journal of Evidence based Medicine and Healthcare; Volume 2, Issue 4, January 26, 2015; Page: 431-439. ABSTRACT: Malaria is currently is a major health problem, which has been attributed to wide spread resistance of the anopheles mosquito to the economical insecticides and increasing prevalence of drug resistance to plasmodium falciparum. Newer drugs are needed as there is a continual threat of emergence of resistance to both artemisins and the partner medicines. Newer artemisinin compounds like Artemisone, Artemisnic acid, Sodium artelinate, Arteflene, Synthetic peroxides like arterolane which is a synthetic trioxolane cognener of artemisins, OZ439 a second generation synthetic peroxide are under studies. Newer artemisinin combinations include Arterolane(150mg) + Piperaquine (750mg), DHA (120mg) + Piperaquine(960mg) (1:8), Artesunate + Pyronardine (1:3), Artesunate + Chlorproguanil + Dapsone, Artemisinin (125mg) + Napthoquine (50mg) single dose and Artesunate + Ferroquine.Newer drugs under development including Transmission blocking compounds like Bulaquine, Etaquine, Tafenoquine, which are primaquine congeners, Spiroindalone, Trioxaquine DU 1302, Epoxamicin, Quinolone 3 Di aryl ether. Newer drugs targeting blood & liver stages which include Ferroquine, Albitiazolium – (SAR – 97276). Older drugs with new use in malaria like beta blockers, calcium channel blockers, protease inhibitors, Dihydroorotate dehydrogenase inhibitors, methotrexate, Sevuparin sodium, auranofin, are under preclinical studies which also target blood and liver stages. Antibiotics like Fosmidomycin and Azithromycin in combination with Artesunate, Chloroquine, Clindamycin are also undergoing trials for treatment of malaria. Vaccines - RTS, S– the most effective malarial vaccine tested to date.
    [Show full text]
  • Drug Targets of the Heartworm, Dirofilaria Immitis
    Drug Targets of the Heartworm, Dirofilaria immitis Inauguraldissertation zur Erlangung des Würde eines Doktors der Philosophie vorgelegt der Philosophisch-Naturwissenschaftlichen Fakultät der Universität Basel von Christelle Godel aus La Sagne (NE) und Domdidier (FR) Schweiz Avenches, 2012 Genehmigt von der Philosophisch-Naturwissenschaftlichen Fakultät auf Antrag von Prof. Dr. Jürg Utzinger Prof. Dr. Pascal Mäser P.D. Dr. Ronald Kaminsky Prof. Dr. Georg von Samson-Himmelstjerna Basel, den 26th of June 2012 Prof. Dr. M. Spiess Dekan To my husband and my daughter With all my love. Table of Content P a g e | 2 Table of Content Table of Content P a g e | 3 Acknowledgements ............................................................................................................... 5 Summary ............................................................................................................................... 8 Introduction ..........................................................................................................................11 Dirofilaria immitis ..............................................................................................................12 Phylogeny and morphology ...........................................................................................12 Repartition and ecology .................................................................................................14 Life cycle .......................................................................................................................16
    [Show full text]
  • Synthetic Ozonide Drug Candidate OZ439 Offers New Hope for a Single-Dose Cure of Uncomplicated Malaria
    Synthetic ozonide drug candidate OZ439 offers new hope for a single-dose cure of uncomplicated malaria Susan A. Charmana, Sarah Arbe-Barnesb, Ian C. Bathurstc, Reto Brund,e, Michael Campbella, William N. Charmana, Francis C. K. Chiua, Jacques Cholletd,e, J. Carl Craftc, Darren J. Creeka, Yuxiang Dongf, Hugues Matileg, Melanie Maurerd,e, Julia Morizzia, Tien Nguyena, Petros Papastogiannidisd,e, Christian Scheurerd,e, David M. Shackleforda, Kamaraj Sriraghavanf, Lukas Stingelina, Yuanqing Tangf, Heinrich Urwylerh, Xiaofang Wangf, Karen L. Whitea, Sergio Wittlind,e, Lin Zhouf, and Jonathan L. Vennerstromf,1 aCentre for Drug Candidate Optimisation, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC 3052, Australia; bFulcrum Pharma Developments Ltd., Hemel Hempstead, Hertfordshire HP1 1JY, United Kingdom; cMedicines for Malaria Venture, CH-1215 Geneva, Switzerland; dSwiss Tropical and Public Health Institute, CH-4002 Basel, Switzerland; eUniversity of Basel, CH-4051 Basel, Switzerland; fCollege of Pharmacy, University of Nebraska Medical Center, Omaha, NE 68198-6025; gF. Hoffmann-La Roche Ltd., CH-4070 Basel, Switzerland; and hBasilea Pharmaceutica Ltd., CH-4058 Basel, Switzerland Edited by Thomas E. Wellems, National Institutes of Health, Bethesda, MD, and approved January 11, 2011 (received for review October 21, 2010) Ozonide OZ439 is a synthetic peroxide antimalarial drug candidate Thai-Cambodian border, and more recently, increased parasite designed to provide a single-dose oral cure in humans. OZ439 has clearance times with artesunate (AS) monotherapy, have raised successfully completed Phase I clinical trials, where it was shown to significant concerns that resistance to these agents may be be safe at doses up to 1,600 mg and is currently undergoing Phase emerging (2, 3).
    [Show full text]
  • New Targets in Malaria Parasite Chemotherapy: a Review
    trol & E on lim C in ia a r t a i l o a n M Malaria Control & Nigussie D, Malaria Contr Elimination 2015, S1:1 DOI: 10.4172/2470-6965/1000S1-007 ISSN: 2470-6965 Elimination Review Article Open Access New Targets in Malaria Parasite Chemotherapy: A Review Dereje Nigussie1*, Takele Beyene2, Naseer Ali Shah3 and Sileshi Belew4 1Ethiopian Public Health Institute, Addis Ababa, Ethiopia, Tel: 011 2 13 34 99; Fax: +00251 1 2754744 / 757722; Email: [email protected] 2Addis Ababa University, College of Agriculture and Veterinary Medicine, Department of Biomedical Science, Debrezeit, Ethiopia 3COMSATS Institute of Information Technology, Department of Biosciences, Islamabad, Pakistan 4Jimma University College of agriculture and Veterinary medicine, P.O. Box 307, Jimma, Ethiopia *Corresponding author: Dereje Nigussie, Vaccines and diagnostic Production directorate, Ethiopian Public Health Institute, P.O. Box 1242, Addis Ababa, Ethiopia, Tel: +251911660850; E-mail: [email protected] Rec date: Oct 31, 2015, Acc date: Nov 24, 2015, Pub date: Nov 30, 2015 Copyright: © 2015 Nigussie D, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Abstract Malaria is a global health problem that causes significant mortality and morbidity annually and a serious problem to drug therapy and discovery as current anti-malarial therapeutics become increasingly ineffective. The need for new therapy for malaria is mandatory because of the emergence of resistance to most of the anti-malarial drugs. There are different approaches and targets proposed by researchers and scientist based on experimental data.
    [Show full text]
  • A Variant Pfcrt Isoform Can Contribute to Plasmodium Falciparum Resistance to the First-Line Partner Drug Piperaquine" (2017)
    Old Dominion University ODU Digital Commons Biological Sciences Faculty Publications Biological Sciences 5-2017 A Variant PfCRT Isoform Can Contribute to Plasmodium Falciparum Resistance to the First- Line Partner Drug Piperaquine Satish K. Dhingra Devasha Redhi Jill M. Combrinck Tomas Yeo John Okombo See next page for additional authors Follow this and additional works at: https://digitalcommons.odu.edu/biology_fac_pubs Part of the Biology Commons, Parasitic Diseases Commons, and the Pharmacology Commons Repository Citation Dhingra, Satish K.; Redhi, Devasha; Combrinck, Jill M.; Yeo, Tomas; Okombo, John; Henrich, Philipp P.; Cowell, Annie N.; Gupta, Purva; Stegman, Matthew L.; Hoke, Jonathan M.; Cooper, Roland A.; Winzeler, Elizabeth; Mok, Sachel; Egan, Timothy J.; and Fidock, David A., "A Variant PfCRT Isoform Can Contribute to Plasmodium Falciparum Resistance to the First-Line Partner Drug Piperaquine" (2017). Biological Sciences Faculty Publications. 211. https://digitalcommons.odu.edu/biology_fac_pubs/211 Original Publication Citation Dhingra, S. K., Redhi, D., Combrinck, J. M., Yeo, T., Okombo, J., Henrich, P. P., . Fidock, D. A. (2017). A variant PfCRT isoform can contribute to Plasmodium falciparum resistance to the first-line partner drug piperaquine. MBio, 8(3). e00303-17 doi:10.1128/ mBio.00303-17 Authors Satish K. Dhingra, Devasha Redhi, Jill M. Combrinck, Tomas Yeo, John Okombo, Philipp P. Henrich, Annie N. Cowell, Purva Gupta, Matthew L. Stegman, Jonathan M. Hoke, Roland A. Cooper, Elizabeth Winzeler, Sachel Mok, Timothy J. Egan, and David A. Fidock This article is available at ODU Digital Commons: https://digitalcommons.odu.edu/biology_fac_pubs/211 Downloaded from RESEARCH ARTICLE crossm mbio.asm.org A Variant PfCRT Isoform Can Contribute on May 16, 2017 - Published by to Plasmodium falciparum Resistance to the First-Line Partner Drug Piperaquine Satish K.
    [Show full text]
  • Dondorp, Background on Malaria and Combination Anti-Malarial Drug Therapy
    Background on Malaria and Combination Anti-Malarial Drug Therapy FDA Workshop: Clinical Trial Design Considerations for Malaria Drug Development 30 June 2016 Prof. Arjen M. Dondorp Mahidol Oxford Tropical Medicine Research Unit The 5 human Plasmodium species P. falciparum P. vivax Anopheles P. knowlesi P. malariae P. ovale H. sapiens M. fascicularis/ nemestrina Life-cycle of Plasmodium White et al; Lancet 2014 Artemisinins: the best drugs for reducing malaria mortality Log-rank p=0.0002 SEAQUAMAT Asia 4 countries N=1,461 Δ=35% (202 children) AQUAMAT Artesunate Africa 9 countries Δ=23% N=5,425 Quinine (all children) Dondorp et al. Lancet 2010; SEAQUAMAT investigators group. Lancet 2005 Broader stage specificity explains superiority of artemisins rapid action, broad stage specificity, safe, easy administration White; Science 2009 Differences in potency TOTAL PARASITES Artesunate best drug to treat severe malaria 1012 Fastest for the artemisinins 1010 Detection limit 108 106 104 104 103 102 10 Reduction/ 48h-cycle 102 MQ, PQP, 0 Artesunate Malarone Doxycycline 0 1 2 3 4 WEEKS = artemisinin resistance Courtesy NJ White Differences in pharmacokinetics 100% M C P Plasma concentration (%) concentration Plasma A Q 0% 0 1 2 3 4 Time after start treatment (weeks) Courtesy NJ White Artemisinin resistance: a prelude to ACT failure 1. W-Cambodia 2007-2008 2012-2013 2012-2014 Slow clearance DHA-piperquine efficacy DHA-piperquine 42-day failures Source CNM Cambodia/ WHO Map by Richard Maude Dondorp et al. Amaratunga et al. N Eng J Med 2009 Lancet Infect Dis 2016 The molecular marker for artemisinin resistance: Kelch 13 K13 mutations in the “propeller region” strongly associates with the slow clearing phenotype multiple SNPs in the propeller region, but: only 1 mutation per clone seems permitted Ariey et al.
    [Show full text]
  • ESCMID Online Lecture Library @ by Author Use of Antimalarials
    Antimalarials for eradication ESCMID Online Lecture Library @ by author Use of antimalarials • Therapy • Prophylaxis • Intermittent preventive therapy in pregnancy • Intermittent preventive therapy in infants • Seasonal intermittent preventive therapy • Mass drug administration AndESCMID something Onlineelse ... Lecture Library @ by author The ideal antimalarial for eradication • Safe • Well tolerated • Efficacious and effective • No population restriction • Cheap • Active against all Plasmodium species • Active against all stages • Active against hypnozoites ESCMID Online Lecture Library @ by author The ideal antimalarial for eradication • One dose • Oral administration • No resistant parasites present • Refractory to resistance development • Fast acting • Long half life • Matching pharmacokinetics ESCMID Online Lecture Library @ by author Single Encounter Radical Cure and Prophylaxis Eliminate the human reservoir of infection Single patient encounter Radical cure leading to elimination of persistent asexual blood-stage forms and hypnozoites Prophylaxis to prevent reinfection for at least 1 month Suitable for mass drug administration (PLOS Medicine 2011) ESCMID Online Lecture Library @ by author ? Which drugs are there ESCMID Online Lecture Library @ by author List of antimalarials (1) Quinolines and combination of quinolines • quinine • quinine-clindamycin • quinine-doxycycline • quinine-tetracycline • quinine-sulfadoxine-pyrimethamine • quinidine • chloroquine • chloroquine-sulfadoxine-pyrimethamine • ESCMIDchloroquine-azithromycin
    [Show full text]
  • Artemisinin and Quinoline Hybrid Compounds Inhibit Replication of SARS-Cov-2 in Vitro
    Artemisinin and Quinoline Hybrid Compounds Inhibit Replication of SARS-CoV-2 In Vitro Lars Herrmann,[a] Ivan A. Yaremenko,[b] Aysun Çapcı,[a] Julia Struwe,[c] Jan Hodek,[d] Yulia Yu. Belyakova,[b] Peter S. Radulov,[b] Grigoriy A. Stepanov,[e] Jan Weber,[d] Alexander O. Terent'ev,*[b] Lutz Ackermann,*[c,f] and Svetlana B. Tsogoeva*[a] [a] L. Herrmann, Dr. A. Çapcı, Prof. Dr. S. B. Tsogoeva Organic Chemistry Chair I and Interdisciplinary Center for Molecular Materials (ICMM) Friedrich-Alexander University of Erlangen-Nürnberg Nikolaus Fiebiger-Straße 10, 91058 Erlangen, Germany E-mail: [email protected] [b] Dr. I. A. Yaremenko, Yu. Yu. Belyakova, Dr. P.S. Radulov, Prof. Dr. A.O. Terent’ev N. D. Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences 47 Leninsky prosp., 119991 Moscow, Russian Federation. E-Mail: [email protected] [c] J. Struwe, Prof. Dr. L. Ackermann Institut für Organische und Biomolekulare Chemie Georg-August-Universität Göttingen Tammannstraße 2, 37077 Göttingen, Germany E-mail: [email protected] [d] Dr. J. Hodek, Dr. J. Weber Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences Flemingovo namesti 2, 16610 Prague, Czech Republic [e] Grigoriy A. Stepanov National Research University Higher School of Economics, Moscow, Russian Federation [f] Prof. Dr. L. Ackermann German Center for Cardiovascular Research (DZHK), Germany Abstract: The newly emerged severe acute respiratory syndrome by the World Health Organization (WHO) on March 11th 2020.[1] coronavirus 2 (SARS-CoV-2) cause life-threatening diseases in Several types of vaccines have already been developed, whereas millions of people worldwide and there is an urgent need for antiviral effective antiviral treatments are lacking.
    [Show full text]